FDA Approves Pimicotinib for TGCT Following Positive Phase 3 MANEUVER Trial Results

Coverage, in order

1. 8h ago
   
   OncoDaily obscure study randomized trial

   FDA Approves Pimicotinib for TGCT Following Positive Phase 3 MANEUVER Trial Results

   The U.S. Food and Drug Administration (FDA) has approved pimicotinib (PIMJETMI), a once-daily oral targeted therapy, for adults with symptomatic tenosynovial giant cell tumor (TGCT) when surgical removal could worsen

Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.